期刊文献+

^(18)F-FDG正电子显像对分化型甲状腺癌术后诊断及预后判定的价值 被引量:1

下载PDF
导出
摘要 目的评估18F-FDG正电子显像对分化型甲状腺癌(DTC)患者术后诊断及预后判定的价值。方法 52例已确诊为DTC并经手术治疗的患者,进行诊断性剂量的全身扫描(DxWBS)及18F-FDG正电子显像;对其中48例再行131I治疗的患者进行治疗剂量的全身扫描(TxWBS)。将18F-FDG正电子扫描结果与DxWBS及TxWBS结果进行对比,并将18F-FDG扫描结果与DTC的分级及预后联系起来进行对照。结果 48例已行131I治疗的患者,TxWBS结果所显示的病灶数量与DxWBS类似1。8F-FDG显像主要显示甲状腺以外的病灶,DxWBS与TxWBS主要显示甲状腺内的病灶1。8F-FDG正电子显像结果阴性的患者大多处于疾病Ⅰ期,同时,所有高于Ⅰ期的患者均为阳性结果。平均30个月的随访中1,8F-FDG正电子结果为阳性的患者肿瘤持续存在或恶化、转移,阴性患者中的极大多数病情逐渐缓解。结论与DxWBS、TxWBS对比,在对DTC术后诊断方面1,8F-FDG正电子显像更容易发现甲状腺外的转移灶,而且,其结果与肿瘤分级及预后有相关性。
出处 《广东医学》 CAS CSCD 北大核心 2010年第24期3235-3238,共4页 Guangdong Medical Journal
  • 相关文献

参考文献14

  • 1JEMAL A,SIEGEL R,WARD E,et al.Cancer statistics,2006[J].CA:A Cancer J Clin,2006,56(2):106-130.
  • 2DAVIES L,WELCH H G.Increasing incidence of thyroid cancer in the United States,1973-2002[J].JAMA,2006,295(18):2164-2167.
  • 3AL NAHHAS A.Dedifferentiated thyroid carcinoma:the imaging role of 18F -FDG-PET and non-iodine radiopharmaceuticals[J].Nucl Medi Commun,2004,25(9):891-895.
  • 4ROBBINS R J,WAN Q,GREWAL R K,et al.Real-time prognosis for metastatic thyroid carcinoma based on 18F-FDG-PET scanning[J].J Clin Endocrinol Metab,2006,91(2):498-505.
  • 5WANG W,LARSON S M,FAZZARI M,et al.Prognostic value of 18F -FDG-PET scanning in patients with thyroid cancer[J].J Clin Endocrinol Metab,2000,85(3):1107-1113.
  • 6ALZAHRANI A S,BAKHEET S,AL MANDIL M,et al.123I isotope as a diagnostic agent in the follow-up of patients with differentiated thyroid cancer:comparison with post 131I therapy whole body scanning[J].J Clin Endocrinol Metabo,2001,86(11):5294-5300.
  • 7WANG W,LARSON S M,TUTTLE R M,et al.Resistance of 18F -FDG-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine[J].Thyroid,2001,11(12):1169-1175.
  • 8李少华,王自正,邵国强,王峰,张乐乐,蒋娥,孟庆乐.抗甲状腺球蛋白抗体和^(18)F-FDG符合线路显像在分化型甲状腺癌随访中的临床应用[J].中国医学影像技术,2008,24(9):1465-1468. 被引量:7
  • 9JEONG H S,BAEK C H,SON Y I,et al.Integrated 18F -FDG-PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma:comparison with ultrasound and contrast-enhanced CT[J].Clin Endocrinol,2006,65(3):402-407.
  • 10DE GEUS OEI L F,PIETERS G F,BONENKAMP J J,et al.18F -FDG-PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results[J].J Nucl Med,2006,47(5):770-775.

二级参考文献14

  • 1Paeini F, Lari R, Mazzeo S, et al. Diagnostic value of single serum thyroglobulin determination on and off thyroid supressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf), 1985,23(4) :405-411.
  • 2Lind P, Kohlfurst S. Respective roles of thyroglobulin radio-iodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin Nucl Med, 2006,36(3) : 194-205.
  • 3Spencer CA, LoPresti JS, Fatemi S, et al. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thyroid, 1999,9(5) : 435-441.
  • 4Girelli ME, De Vido D. Serum thyroglobulin measurements in differentiated thyroid cancer. Biomed Pharmacother, 2000, 54 (6) : 330-333.
  • 5Schlumberg MJ. Diagnostie follow-up of well differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest, 1999,22 (1): 3-7.
  • 6Duren M, Siperstein AE, Shen W, et al. Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery, 1999,126(1) : 13-19.
  • 7Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of ^131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 2005,90(3) : 1440-1445.
  • 8Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab, 1998, 83 (4) : 1121-1127.
  • 9Vincze B, Sinkovics I, Keresztes S, et al. Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation. Magy Onkol, 2004, 48 (1) :27-34.
  • 10Hammami H, Sellem A, Ben Sellem D, et al. Thyroglobulin: usefulness and limits in monitoring patient with thyroid carcinoma. Tunis Med, 2007,85(2):128-130.

共引文献6

同被引文献6

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部